Innova Biosciences and Mologic sign supply and licensing agreement


27-07-2015

Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use of Innova’s Lightning-Link® and InnovaCoat® GOLD technologies as part of Mologic’s commercial assay development services and range of immunoassays.

 

The deal provides Mologic with rights to incorporate Innova Technology into its products, including its full point of care diagnostic portfolio in addition to its B.I.T.S.™ range of high quality laboratory diagnostic assays.  The agreement also allows Mologic to provide its customers direct access to Innova’s leading technology when incorporated into product development programmes.

Lightning-Link is the fastest, easiest to use, most efficient antibody conjugation method available. Requiring only 30 seconds hands-on time, with no separation steps and 100% antibody recovery, Lightning-Link provides highly stable conjugates due to its covalent bonding mechanism.

InnovaCoat GOLD is a one-step kit for conjugation of antibodies, proteins and peptides or any other biomolecule with an amine group, using gold nanoparticles. The superior quality gold nanoparticles have a proprietary surface coating, which enhances colloidal stability and enables covalent linking of the nanoparticle to an antibody.

Dr Nick Gee, CEO of Innova Biosciences, commented: “We are delighted to sign this agreement with Mologic, which forms part of our strategy of working with high-quality partners. The Company has an excellent reputation in immunoassay development, and we see their decision to work with Lightning-Link and InnovaCoat GOLD as a powerful endorsement of our technologies.”

Mark Davis, CEO of Mologic, said: “We have already benefitted from using Innova’s conjugation technology and have seen excellent results across the product range.  The simplicity of Lightning-Link kits has led to them becoming essential tools for our highly efficient research group. Extending the relationship to a formal supply and licensing agreement will enable us to continue using the technologies in assay development, and as part of our custom services and disruptive product pipeline. We look forward to working with Innova further.”

Innova’s bioconjugation technologies have a wide range of applications across biological research, and in the development and manufacturing of diagnostic kits. The expanding portfolio is supplied to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide.



About Innova Biosciences Limited

Innova Biosciences is a rapidly growing, dynamic business based at Babraham, Cambridge at the heart of the UK’s leading innovation centre. At the core of Innova's business are bioconjugation and nanoparticle technologies including Lightning-Link®, InnovaCoat® and Thunder-Link® brands, which provide easy to use kits which overcome many of the problems associated with traditional bioconjugation. Innova’s products are suitable for both small scale R&D applications and large scale manufacturing.

For more information, please see www.innovabiosciences.com

About Mologic

Mologic, having recently regained its independence, is entering into an exciting phase of product development and commercialisation, bringing to market its entire range of diagnostic and patient management technology established during the past 5 years of dedicated research.  This portfolio contains a home based Cystic Fibrosis Exacerbation Monitor, a Peritoneal Dialysis Infection Diagnostic, a Sepsis Diagnostic and a series of technically related products monitoring the host inflammatory response, all at the point of care and/or in the home.  These products are aimed at bringing early warning of disease progression to the patient in the home or to the care provider in the professional environment.  This will not only bring forward the use of appropriate treatment but will also reduce the burden on healthcare resources whilst improving the quality of life for patients with chronic disease.

Underpinning these technical developments, Mologic has maintained its vibrant contract partnering group that continues to deliver high quality innovation and applied development in the sectors of diagnostics and vaccine development for both human and non-human applications.  

For more information, please see www.mologic.co.uk

*******

Media contacts

Katie Odgaard, Zyme Communications
Email: katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947

At Innova Biosciences
Dr Andy Lane, Executive Director
Email: andy.lane@innovabiosciences.com
Phone: +44 (0) 1223 496 170

At Mologic
Mark Davis, CEO
Email:  mark.davis@mologic.co.uk
Phone: +44 (0)1234 780020
_________________________________________________________

 

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Research Campus Ltd.